According to New Data Released at TCT 2016 Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR CAESAREA, Israel, and TAMPA, Florida –November 1, 2016 — Keystone Heart Ltd., an emerging medical device company focused on developing cerebral embolic...
CAESAREA, Israel and TAMPA, Fla., Oct. 3, 2016 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients undergoing cardiovascular procedures, announces data recently published in the American Journal of Cardiology demonstrating new brain lesions in 94% of patients undergoing transcatheter aortic...
CAESAREA, Israel and TAMPA, Fla., Sept. 19, 2016 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients undergoing cardiac procedures, today announces the safety and efficacy of the TriGuard™ Cerebral Embolic Protection device when used during Transcatheter Aortic Valve Replacement (TAVR), according to...
Supporting data to be presented at Transcatheter Valve Therapies (TVT) Conference Keystone Heart Ltd. Announces First Patient Enrolled in New Study to Protect the Brain During TAVR CAESAREA, Israel & TAMPA, Fla.–(BUSINESS WIRE)–Keystone Heart Ltd., an emerging medical device...
Sign Up for Keystone Heart Updates
EU
US